Preoperative Chemotherapy with DCF for Advanced Esophageal Cancer
Murata, K.; Kuroda, D.; Okamoto, S.; Fujinaka, R.; Arai, K.; Otowa, Y.; Mii, Y.; Kakinoki, K.; Mani, M.; Oka, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(8): 1337-1339
2019
ISSN/ISBN: 0385-0684 PMID: 31501384 Document Number: 699645
We conducted a retrospective study to evaluate the efficacy and the problem of the neoadjuvant chemotherapy using DCF for cStage Ⅲ/Ⅳ(squamous cell)esophageal cancer. Eleven patients from January 2017 to December 2018 were enrolled into this study. The median age was 67 years old, male/female ratio was 9:2, performance status was 0 in all patients, and UICC cStage Ⅲ/Ⅳa was 7:4. Cycles of chemotherapy was 2 in 1 patients, 3 in 5 patients and additional 2 courses in 1 patient. Four patients switched to FP therapy after a course of DCF. The efficacy of chemotherapy was evaluated by the clinical response rate, average tumor reduction rate, and histological therapeutic effect rate over Grade 2 which was 63.6%, 48.3%, and 40%, respectively. Neutropenia over Grade 3 was observed in all patients and Grade 4 was observed in 6 patients. In conclusion, preoperative chemotherapy with DCF therapy is useful for the treatment of cStage Ⅲ/Ⅳ(squamous cell) esophageal cancer as long as bone marrow suppression is managed.